Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Common Equity (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Common Equity for 16 consecutive years, with $13.7 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 78.32% to $13.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.7 million through Dec 2025, down 78.32% year-over-year, with the annual reading at $13.7 million for FY2025, 78.32% down from the prior year.
  • Common Equity for Q4 2025 was $13.7 million at Harvard Bioscience, down from $14.1 million in the prior quarter.
  • The five-year high for Common Equity was $83.4 million in Q4 2021, with the low at $13.7 million in Q4 2025.
  • Average Common Equity over 5 years is $61.7 million, with a median of $72.6 million recorded in 2022.
  • The sharpest move saw Common Equity increased 8.76% in 2021, then tumbled 78.46% in 2025.
  • Over 5 years, Common Equity stood at $83.4 million in 2021, then decreased by 13.41% to $72.2 million in 2022, then grew by 1.18% to $73.1 million in 2023, then decreased by 13.32% to $63.3 million in 2024, then plummeted by 78.32% to $13.7 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $13.7 million, $14.1 million, and $15.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.